Drug therapeutic failures in emergency department patients: A university hospital experience

Pharmacological Research

Volumn 49, Issue 1, 2004, Pages 85-91

  Franceschi, Alessandro ^a   Tuccori, Marco ^a   Bocci, Guido ^a   Vannozzi, Francesca ^a   Di Paolo, Antonello ^a   Barbara, Cecilia ^a   Lastella, Marianna ^a   Blandizzi, Corrado ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adverse drug reaction; Drug therapeutic failure; Emergency department; Lack of efficacy; Pharmacovigilance

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CARBAMAZEPINE; CARDIAC GLYCOSIDE; CEFTRIAXONE; CENTRAL DEPRESSANT AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; ENALAPRIL; FUROSEMIDE; GLUCOCORTICOID; INSULIN; METHYLPREDNISOLONE; METILDIGOXIN;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE DISEASE; BRONCHITIS; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG FEVER; DRUG IDENTIFICATION; DRUG UTILIZATION; DYSPNEA; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; EPILEPSY; FEMALE; FREQUENCY ANALYSIS; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INTERVIEW; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEIZURE; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VASCULITIS;

EID: 0142184376     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.08.001     Document Type: Article

References (21)

1. World Health Organization and The WHO Collaborating Centre for International Drug Monitoring. The importance of pharmacovigilance - safety monitoring of medicinal products. Uppsala, Sweden; 2002.
2. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 356:2000;1255-1259.
3. Beard K. Adverse reactions as a cause of hospital admissions in the aged. Drugs Aging. 2:1992;356-367.
4. Patel B., Zed P.J. Drug-related visit to the emergency department: how big is the problem? Pharmacotherapy. 22:2002;915-923.
5. Hafner J.W., Belknap S.M., Squillante M.B., Bucheit K.A. Adverse drug events in emergency department patients. Ann. Emerg. Med. 39:2002;258-267.
6. Figueras A., Pedros C., Valsecia M., Laporte J.R. Therapeutic ineffectiveness. Heads or tails? Drug Saf. 25:2002;485-487.
7. Meyboom R.H.B., Lindquist M., Flygare A.K., Biriell C., Edwards I.R. The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Saf. 23:2000;95-99.
8. Hartigan-Go KY, Wong JQ. Inclusion of therapeutic failures as adverse drug reactions. In: Aronson JK, editor. Side effects of drugs. Annual 23. A worldwide yearly survey of new data and trends in adverse drug reaction. Amsterdam: Elsevier; 2000. p. 27-33.
9. Hallas J., Harvald B., Worm J., Beck-Nielsen J., Gram L.F., Grodum E.et al. Drug related hospital admissions. Results from an intervention program. Eur. J. Clin. Pharmacol. 45:1993;199-203.
10. Raschetti R., Morgutti M., Menniti-Ippolito F., Belisari A., Rossignoli A., Longhini P.et al. Suspect adverse drug events requiring emergency department visits or hospital admissions. Eur. J. Clin. Pharmacol. 54:1999;959-963.
11. Martìn M.T., Codina C., Tuset M., Carné X., Nogué S., Ribas J. Problemas relacionados con la medicación como causa del ingreso hospitalario. Med. Clin. (Barc). 118:2002;205-210.
12. Hallas J., Harvald B., Gram L.F., Grodum E., Brøsen K., Haghfelt T.et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J. Int. Med. 228:1990;83-90.
13. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am. Heart J. 130:1995;572-579.
14. Worrel J.A., Marken P.A., Beckman S.E., Ruehter V.L. Atypical antipsychotic agents: a critical review. Am. J. Health Syst. Pharm. 57:2000;238-255.
15. Gumnick J.F., Nemeroff C.B. Problems with currently available antidepressants. J. Clin. Psychiatry. 61(Suppl. 10):2000;5-15.
16. Issa A.M. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1:2002;300-308.
17. Nebert D.W. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet. 56:1999;247-258.
18. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100:1997;3184-3188.
19. Drazen J.M., Yandava C.N., Dube L., Szczerback N., Hippensteel R., Pillari A.et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22:1999;168-170.
20. Sjogren M., Hesse C., Basun H., Kol G., Thostrup H., Kilander L.et al. Tacrine and rate of progression in Alzheimer's disease - relation to ApoE allele genotype. J. Neural Transm. 108:2001;451-458.
21. Ordovas J.M., Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13:2002;113-137.